Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

Recruiting now · Phase 4

Conditions studied: Hypertrophic Cardiomyopathy (HCM)

In brief

This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).

Key facts

Study ID

NCT07600177

Run by

Oregon Health and Science University

People needed

40

Starts

2026-05-05

Expected to finish

2027-03-15

Last updated by the study team

2026-05-20

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented history of oHCM with documented resting and/or Valsalva LVOT obstruction ≥ 50 mmHg who are currently receiving mavacamten commercially.
• Echo-derived LVEF ≥55% on mavacamten at the time of enrollment.
• Patient willing to consent for the study and undergo the study procedures.

You may not qualify if…

• Severe aortic stenosis or sub-aortic obstruction
• Known infiltrative or storage disorder causing cardiac hypertrophy that mimics HCM (eg, Noonan syndrome, Fabry disease, amyloidosis).
• History of LVEF <30%.
• Paroxysmal atrial fibrillation (AF) with documented episode within 3 months.
• Atrial fibrillation (paroxysmal or permanent) not on systemic anticoagulation.
• Documented history of current obstructive coronary artery disease (> 70% stenosis in one or more epicardial coronary arteries) or documented history of myocardial infarction.

Where it is running

• Oregon Health & Science University — Portland, Oregon, United States (enrolling)
• St. Luke's Hospital - Mid America Heart Institute — Kansas City, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.